Document is current
Any future updates will be listed below
-
Authors
Malic, Lidija
Zhang, Peter G. Y.
Plant, Pamela J.
Clime, Liviu
Nassif, Christina
Da Fonte, Dillon
Haney, Evan E.
Moon, Byeong-Ui
Sit, Victor Min-Sung https://orcid.org/0009-0001-8897-6555
Brassard, Daniel
Mounier, Maxence
Churcher, Eryn https://orcid.org/0009-0006-1269-7492
Tsoporis, James T.
Falsafi, Reza
Bains, Manjeet
Baker, Andrew
Trahtemberg, Uriel https://orcid.org/0000-0001-9103-2494
Lukic, Ljuboje
Marshall, John C. https://orcid.org/0000-0002-7902-6291
Geissler, Matthias
Hancock, Robert E. W. https://orcid.org/0000-0001-5989-8503
Veres, Teodor
dos Santos, Claudia C. https://orcid.org/0000-0002-6446-8791
-
Funding
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (FDN-420463)
Canada Research Chairs (CRC2024)
- License Information
-
More Information
Article History
Received: 11 October 2024
Accepted: 15 April 2025
First Online: 27 May 2025
Competing interests
: REWH is an inventor of the Sepset signature that has been patented in 17 countries (e.g. US patent 11,851,717 issued Dec 26, 2023) and is CEO and a shareholder of Asep Medical and its subsidiary Sepset BioSciences Inc. that have licensed in these patents and are actively commercially developing sepsis diagnostics. REWH also has a contract from Sepset Biosciences for development of diagnostic assays for adult sepsis. PGYZ and EFH are employees of Sepset Biosciences Inc. and/or Asep Medical. The PREDICT device is patented e.g. US20170036208A1 with Teodor Veres as a patent holder and assigned to his employer National Research Council of Canada. The remaining authors declare no competing interests.
